Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marty Schmidt

Pediatrics Hobbs, NM Medical Doctor

NPI 1639130248 CMS profile 950776

2410 N Fowler St, Hobbs, NM 88240

Open in the dashboard

General payments

$306

18 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marty Schmidt of Hobbs, NM is reported in the CMS Open Payments database as having received $306 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $104 5
2023 General $35 2
2022 General $57 3
2021 General $53 4
2020 General $30 2
2019 General $26 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marty Schmidt
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Marty Schmidt were reported at $104. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Marty Schmidt Pediatrics median Middle half National median
2019 $26 $86 $31–$183 $163
2020 $30 $49 $22–$110 $114
2021 $53 $68 $27–$158 $132
2022 $57 $77 $30–$173 $149
2023 $35 $88 $33–$190 $160
2024 $0 $94 $34–$206 $164
2025 $104 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $65 5 payments
  2. Otsuka America Pharmaceutical, Inc. $46 2 payments
  3. Adlon Therapeutics L.P. $45 3 payments
  4. ITI, Inc. $38 2 payments
  5. Amgen Inc. $36 2 payments
  6. E.R. Squibb & Sons, L.L.C. $21 1 payment
  7. AbbVie, Inc. $20 1 payment
  8. Sanofi Pasteur Inc. $18 1 payment
  9. Corium, Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $306 18 payments
Products named General payments · program years 2019–2025
  1. REXULTI $46 2 payments
  2. ADHANSIA XR $45 3 payments
  3. TRELEGY ELLIPTA $41 3 payments
  4. CAPLYTA $38 2 payments
  5. Otezla $36 2 payments
  6. Repatha $36 2 payments
  7. BEXSERO $24 2 payments
  8. PEDIARIX $24 2 payments
  9. MENVEO $24 2 payments
  10. CAMZYOS $21 1 payment
  11. Other $91 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 122 drugs

Part D claims

6,066

Median for Pediatric Medicine: 38

Drug cost

$335,053

Median for Pediatric Medicine: $2,769

Branded share of claims

23.6%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 73 $81,015
Januvia Sitagliptin Phosphate Brand 40 $53,502
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 35 $27,403
Farxiga Dapagliflozin Propanediol Brand 18 $18,984
Breo Ellipta Fluticasone/Vilanterol Brand 25 $17,505
Eliquis Apixaban Brand 22 $16,502
Linzess Linaclotide Brand 21 $13,911
Albuterol Sulfate Hfa Albuterol Sulfate Brand 252 $6,922
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 11 $6,813
Methocarbamol Generic 20 $6,626

The 10 drugs with the highest cost, of 122 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$4,474

Medicare's payments for the services billed

Medicare patients

58

Average age 71

Services billed

182

41 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 45%
Ischemic heart disease 29%
Depression 28%
Heart failure 21%
Chronic kidney disease 21%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record